Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 3.9% - Should You Sell?

Key Points

• Arcturus Therapeutics shares fell by 3.9% to $18.72, with an increased trading volume compared to the average.
• Despite the stock's recent decline, analysis from various brokerages shows a generally positive outlook with an average price target of $50.00 and most rating it as a "Moderate Buy."
• The company reported better-than-expected earnings for the last quarter, with a loss of ($0.34) per share versus an anticipated ($1.11), alongside revenue of $28.30 million.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) shares traded down 3.9% on Monday . The stock traded as low as $18.13 and last traded at $18.72. 494,793 shares traded hands during trading, an increase of 6% from the average session volume of 467,303 shares. The stock had previously closed at $19.48.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ARCT. Wall Street Zen upgraded Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Canaccord Genuity Group cut their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Wells Fargo & Company decreased their price target on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating for the company in a research note on Tuesday, August 12th. Scotiabank restated an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. Finally, Citigroup reaffirmed a "buy" rating and set a $49.00 price target (up from $47.00) on shares of Arcturus Therapeutics in a research note on Tuesday, August 12th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Arcturus Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $50.00.

Arcturus Therapeutics Trading Down 8.1%

The business has a fifty day simple moving average of $13.57 and a 200 day simple moving average of $13.28. The stock has a market capitalization of $486.35 million, a P/E ratio of -8.03 and a beta of 2.26.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.77. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. The firm had revenue of $28.30 million during the quarter, compared to analyst estimates of $17.64 million. As a group, research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ARCT. Geode Capital Management LLC raised its stake in shares of Arcturus Therapeutics by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company's stock valued at $9,421,000 after buying an additional 3,186 shares during the period. Wells Fargo & Company MN raised its stake in Arcturus Therapeutics by 12.6% in the 4th quarter. Wells Fargo & Company MN now owns 69,664 shares of the biotechnology company's stock valued at $1,182,000 after acquiring an additional 7,785 shares during the period. MetLife Investment Management LLC boosted its position in Arcturus Therapeutics by 21.5% during the fourth quarter. MetLife Investment Management LLC now owns 16,676 shares of the biotechnology company's stock worth $283,000 after purchasing an additional 2,955 shares during the period. Hsbc Holdings PLC boosted its position in Arcturus Therapeutics by 11.8% during the fourth quarter. Hsbc Holdings PLC now owns 25,368 shares of the biotechnology company's stock worth $424,000 after purchasing an additional 2,673 shares during the period. Finally, MGO One Seven LLC increased its stake in shares of Arcturus Therapeutics by 5.6% in the fourth quarter. MGO One Seven LLC now owns 41,350 shares of the biotechnology company's stock worth $702,000 after purchasing an additional 2,204 shares in the last quarter. Institutional investors own 94.54% of the company's stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.